Appendix 1.

Some information about 84 women in this cohort have been previously reported here:

- Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. April 2020:NEJMc2009316. doi:10.1056/NEJMc2009316
- 2. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. *Am J Obstet Gynecol MFM*. May 2020:100134. doi:10.1016/j.ajogmf.2020.100134
- 3. Penfield CA, Brubaker SG, Limaye MA, et al. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples. *Am J Obstet Gynecol MFM*. May 2020:100133. doi:10.1016/j.ajogmf.2020.100133

Appendix 2. Medical and Obstetric Co-Morbidities of SARS-CoV-2 Cohort (N=241)

Characteristic	no./total no. (%)		
Acute or chronic comorbidities			
Anemia	16/241 (6.6)		
Asthma	12/241 (5)		
Pre-existing cardiac disease	2/241 (0.8)		
Diabetes Type 1	1/241 (0.4)		
Diabetes Type 2	8/241 (3.3)		
Sickle cell disease	1/241 (0.4)		
HIV	1/241 (0.4)		
Chronic or essential hypertension	10/241 (4.1)		
Severe preeclampsia or eclampsia	17/241 (7.1)		
Preeclampsia	6/241 (2.5)		
Gestational hypertension	15/241 (6.2)		
Gestational diabetes	27/241 (11.2)		
Abnormal placentation (previa, accreta, etc.)	2/241 (0.8)		
Previous cesarean	34/241 (14.1)		
None	128/241 (53.1)		
Other	27/241 (11.2)		

Appendix 3. Presenting Obstetric and COVID-19 Related Symptoms Among SARS-CoV-2 Cohort (N=241)

Characteristic	no./total no. (%)				
Presenting obstetric symptoms					
Contractions / labor	104/241 (43.2)				
Induction of labor	55/241 (22.8)				
Spontaneous rupture of membranes	41/241 (17)				
Planned cesarean delivery	21/241 (8.7)				
Vaginal bleeding	12/241 (5)				
Decreased fetal movement	8/241 (3.3)				
Other	8/241 (3.3)				
None	26/241 (10.8)				
Presenting COVID-19 symptoms					
Cough	54/241 (22.4)				
Fever	46/241 (19.1)				
Shortness of breath	19/241 (7.9)				
Myalgia	12/241 (5)				
Headache	10/241 (4.1)				
Loss of smell (anosmia)	9/241 (3.7)				
Sore throat	8/241 (3.3)				
Nasal congestion	7/241 (2.9)				
Gastrointestinal symptoms	6/241 (2.5)				
Loss of taste (ageusia)	6/241 (2.5)				
Other†	6/241 (2.5)				
None	148/241 (61.4)				

[†] chest pain, pink sputum, ear fullness, night sweats

Appendix 4. COVID-19 Severity Criteria

Severity	Pre sent ing sym pto ms	Tem p > 100. 4	Ches t CT findi ngs	CXR findi ngs	O2 sat <= 93	ARD S	Vent ilati on	AKI	Seps is	Trache otomy	Cardiac Arrest	Shock
Mild	67.2	54.7	0	0	0	0	0	0	0	0	0	0
(n=64)	%	%										
Severe	63.5	49.2	3/4(32/4	71.4	0	0	0	0	0	0	0
(n=63)	%	%	75%)	0(80	%							
				%)								
Critical	83.3	50.0	2/3(11/1	83.3	58.3	75.0	16.7	8.3%	16.7%	8.3%	8.3%
(n=12)	%	%	66.6	1(10	%	%	%	%				
			%)	0%)								

CXR: Chest x-ray; ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney Injury

Appendix 5. Maternal Vitals and Laboratory Data During Hospitalization

	no.	Median (IQR) [range]
Peak temperature	241	99.4 (98.8,100.8) [97-103.2]
Maximum temp ≥ 100.4 °	241	72 (29.9%)
Fahrenheit		
O2 saturation - nadir	239	96 (94,97) [60-100]
WBC - peak	239	11.7 (8.9,15.2) [3.4-29.9]
WBC - nadir	207	7.7 (6.2,9.6) [1.3-18.7]
Lymphocytes - peak	185	19.8 (16,25) [2.45-58]
Lymphocytes - nadir	130	10.3 (7,14.7) [0.6-39]
Platelets - peak	237	214 (173,278) [79-917]
Platelets - nadir	205	177 (136,223) [58-477]
ALT - peak	130	22 (14,44) [7-602]
ALT - nadir	90	17 (12,26) [5-197]
AST - peak	131	32 (23,60) [13-476]
AST - nadir	90	25 (20,38) [12-103]
LDH - peak	109	276 (219,356) [151-872]
LDH - nadir	68	234.5 (186,286) [120-688]
Procalcitonin - peak	73	0.1 (0.1,0.4) [0-12.5]
Procalcitonin - nadir	40	0.01(0.01,0.4) [0-1.9]
CRP - peak	82	16.65 (3.5,102.1) [0.1-291.2]
CRP - nadir	46	9.3 (2.3,81.6) [0.1-212.6]

WBC: White Blood Cells; ALT: Alanine Aminotransferase; AST: Aspartate Transaminase; LDH: Lactate Dehydrogenase; CRP: C-reactive protein

Appendix 6. Patient Characteristic by Severity of SARS-CoV-2 Infection/COVID-19

	Severity of COVID-19					
	Asymptomatic/Mild	Severe/Critical	p-value*			
Age			.23			
Age < 25 years	35 (77.8)	10 (22.2)				
Age 25-35 years	88 (67.2)	43 (32.8)				
Age > 35 years	43 (66.2)	22 (33.9)				
Race/Ethnicity			.19			
Black, non-Hispanic	68 (70.1)	29 (29.9)				
White, non-Hispanic	13 (54.2)	11 (45.8)				
Hispanic (Latinx)	52 (77.6)	15 (22.4)				
Other	23 (69.7)	10 (30.3)				
BMI			.001			
< 25	15 (88.2)	2 (11.8)				
25-29.99	46 (73.0)	17 (27.0)				
30-39.99	49 (58.3)	35 (41.7)				
40 or greater	6 (42.9)	8 (57.1)				
Insurance status†			.73			
Medicare/Medicaid	96 (67.6)	46 (32.4)				
Private/Commercial	60 (66.8)	26 (30.2)				
Hypertensive disorder			.09			
No	141 (71.2)	57 (28.8)				
Yes	25 (58.1)	18 (41.9)				
Glucose intolerance			.06			
No	146 (71.2)	59 (28.8)				
Yes	20 (55.6)	16 (44.4)				
Mode of delivery			<0.001			
Vaginal birth	110 (78.0)	31 (22.0)				
Cesarean birth	56 (56.0)	44 (44.0)				
Pregnancy length [‡]			.01			
Term	148 (72.9)	55 (27.1)				
Preterm < 37 weeks	18 (50.0)	18 (50.0)				

^{*}corresponds to a Cochran-Armitage trend test (ordinal variables) or chi-square test for association (nominal variables); †n=13 patients did not have insurance type available; ‡out of the number of women who delivered live births (n=239)

Khoury R, Bernstein PS, Debolt C, Stone J, Sutton DM, Simpson LL, et al. Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at five New York City medical centers. Obstet Gynecol 2020;136.

The authors provided this information as a supplement to their article. © 2020 American College of Obstetricians and Gynecologists.